How Full-Life Technologies is using US$150m to push beyond platform promise
Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.
Pharma & Biotech
Pharma & Biotech
Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?
Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.
Pharma & Biotech
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Medical Devices & Diagnostics
Why Telix is taking PSMA-PET deeper into minimally invasive prostate cancer treatment
Prostate ablation is getting more precise. Telix wants PSMA-PET to become the imaging layer that helps clinicians decide where to treat.
Pharma & Biotech
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.
Medical Devices & Diagnostics
Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.
Pharma & Biotech
Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer
Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.
Pharma & Biotech
From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Pharma & Biotech
How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.
Medical Devices & Diagnostics
Why PanGIA Biotech’s urine biopsy data may matter more than the headline sensitivity figure suggests
PanGIA Biotech reported 97.8% sensitivity in a urine-based prostate cancer study. Read what the data changes and what risks still remain.